Douglas Calder
Director/Board Member at ZEVRA THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
Douglas W.
Calder is an Independent Director at Zevra Therapeutics, Inc. since 2023.
He is also a Director at BioFlorida, Inc. since 2019, a Director at Nextgennk since 2019, and a Member at Society For Natural Immunity since 2018.
Previously, he held positions as the Director of Investor Relations & Public Relations at Accentia Biopharmaceuticals, Inc. from 2012 to 2013, President & Director at Vycellix, Inc., VP of Strategic Planning & Capital Markets at BioVest International, Inc. from 2012 to 2013, Executive Vice President at Pulse Evolution Corp., President at VyGen-Bio, Inc., Portfolio Manager at Dean Witter Reynolds, Inc., and Portfolio Manager at Gruntal & Co. LLC.
He completed his undergraduate degree at Florida State University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
-.--% | 2024-05-12 | 0 ( -.--% ) | - $ | 2024-04-29 |
Douglas Calder active positions
Companies | Position | Start |
---|---|---|
ZEVRA THERAPEUTICS, INC. | Director/Board Member | 2023-04-24 |
Nextgennk | Director/Board Member | 2019-05-31 |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013. | Director/Board Member | 2018-12-31 |
Former positions of Douglas Calder
Companies | Position | End |
---|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | Investor Relations Contact | 2013-07-15 |
ACCENTIA BIOPHARMACEUTICALS INC | Investor Relations Contact | 2013-03-03 |
Dean Witter Reynolds, Inc. | Corporate Officer/Principal | - |
Gruntal & Co. LLC | Corporate Officer/Principal | - |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Part of Coeptis Therapeutics Holdings, Inc., VyGen-Bio, Inc. develops cell and gene therapies and treatments for cancer. The company is based in Tampa, FL. The CEO of the company is Evren Alici. VyGen-Bio was acquired by Coeptis Therapeutics Holdings, Inc. | President | - |
Training of Douglas Calder
Florida State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ZEVRA THERAPEUTICS, INC. | Health Technology |
PULSE EVOLUTION CORPORATION | Technology Services |
Private companies | 8 |
---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | Health Technology |
Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Accentia Biopharmaceuticals, Inc. engages in the commercialization of patent-protected disruptive healthcare technologies. It offers products under the BiovaxID., Revimmune, and SinuNase brands. The company was founded in 2002 and is headquartered in Tampa, FL. | Health Technology |
Dean Witter Reynolds, Inc. | Finance |
Gruntal & Co. LLC | Government |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013. | Commercial Services |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Health Technology |
Nextgennk | |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Part of Coeptis Therapeutics Holdings, Inc., VyGen-Bio, Inc. develops cell and gene therapies and treatments for cancer. The company is based in Tampa, FL. The CEO of the company is Evren Alici. VyGen-Bio was acquired by Coeptis Therapeutics Holdings, Inc. | Health Technology |
- Stock Market
- Insiders
- Douglas Calder